---
title: "Regulus Therap (RGLS.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/RGLS.US.md"
symbol: "RGLS.US"
name: "Regulus Therap"
industry: "生物技術"
---

# Regulus Therap (RGLS.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |

## Company Profile

Regulus Therapeutics Inc.是一家臨床階段的生物制藥公司，專注于發現和開發針對微小 RNA 的藥物，以治療美國範圍內的多種疾病。該公司正在開發 farabursen，這是一種針對 miR-17 的抗 miR 寡核苷酸，目前正在進行 1b 期臨床試驗，旨在治療常染色體顯性多囊腎病。它還在開發一系列針對特定靶器官遞送策略的臨床前藥物產品。該公司與 Alnylam Pharmaceuticals, Inc.簽訂了許可和合作協議

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -12.98 | 545/605 | - | - | - |
| PB | 8.94 | 421/605 | 8.94 | 8.94 | 6.81 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.16 |
| Highest Target | 11.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/RGLS.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/RGLS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/RGLS.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.